GlassScriptPhysician profile
James C Anderson
NPI 1952348146
$669,094.40
in general payments reported to CMS, 2019-2025
10 companies · $98K in 2025
The $98K reported for 2025 was more than what 99% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38K · 2020: $13K · 2021: $83K · 2022: $104K · 2023: $237K · 2024: $96K · 2025: $98K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $265K · Travel and Lodging: $62K · Consulting Fee: $50K · Honoraria: $40K · Food and Beverage: $15K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $264,619.00 |
| Travel and Lodging | $62,130.69 |
| Consulting Fee | $50,267.50 |
| Honoraria | $39,600.00 |
| Food and Beverage | $14,606.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $238,050.18 | 2021-2025 | Azstarys, Azstarys |
| Ironshore Pharmaceuticals INC. | $195,164.37 | 2019-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $179,669.74 | 2021-2025 | Qelbree, Qelbree |
| Collegium Pharmaceutical, INC. | $48,979.85 | 2025 | Jornay Pm |
| Neos Therapeutics, LP | $6,062.33 | 2019-2023 | Adzenys Xr-Odt |
| Aytu Biopharma, INC. | $1,000.00 | 2021-2025 | |
| Noven Pharmaceuticals, INC. | $120.13 | 2024 | Xelstrym |
| Novo Nordisk INC | $18.87 | 2025 | Ozempic |
| Pfizer INC. | $14.76 | 2020 | |
| Dexcom, INC. | $14.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.